Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Bought by Western Wealth Management LLC

Western Wealth Management LLC raised its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 3,623 shares of the medical equipment provider’s stock after buying an additional 103 shares during the quarter. Western Wealth Management LLC’s holdings in Intuitive Surgical were worth $1,222,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ISRG. Vanguard Group Inc. boosted its position in shares of Intuitive Surgical by 0.7% during the third quarter. Vanguard Group Inc. now owns 29,868,227 shares of the medical equipment provider’s stock worth $8,730,184,000 after buying an additional 196,316 shares during the period. Geode Capital Management LLC boosted its position in shares of Intuitive Surgical by 1.0% during the first quarter. Geode Capital Management LLC now owns 6,444,995 shares of the medical equipment provider’s stock worth $1,642,287,000 after buying an additional 61,659 shares during the period. Morgan Stanley boosted its position in shares of Intuitive Surgical by 29.9% during the fourth quarter. Morgan Stanley now owns 5,866,613 shares of the medical equipment provider’s stock worth $1,556,706,000 after buying an additional 1,351,002 shares during the period. Jennison Associates LLC boosted its position in shares of Intuitive Surgical by 6.4% during the third quarter. Jennison Associates LLC now owns 4,585,190 shares of the medical equipment provider’s stock worth $1,340,205,000 after buying an additional 274,692 shares during the period. Finally, Invesco Ltd. boosted its position in shares of Intuitive Surgical by 6.6% during the third quarter. Invesco Ltd. now owns 3,750,490 shares of the medical equipment provider’s stock worth $1,096,231,000 after buying an additional 232,205 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Stock Down 1.7 %

Shares of NASDAQ:ISRG opened at $366.34 on Friday. The company’s fifty day moving average is $386.84 and its two-hundred day moving average is $343.10. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $403.76. The company has a market cap of $129.85 billion, a P/E ratio of 66.13, a price-to-earnings-growth ratio of 5.78 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 13.27%. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. During the same period in the previous year, the business earned $1.00 EPS. The company’s revenue was up 11.5% on a year-over-year basis. Equities research analysts anticipate that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current year.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, VP Fredrik Widman sold 5,041 shares of the stock in a transaction on Friday, March 15th. The shares were sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the transaction, the vice president now directly owns 110 shares of the company’s stock, valued at $43,677.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Intuitive Surgical news, VP Fredrik Widman sold 5,041 shares of the stock in a transaction on Friday, March 15th. The shares were sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the transaction, the vice president now directly owns 110 shares of the company’s stock, valued at $43,677.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Marshall Mohr sold 108,790 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the transaction, the vice president now directly owns 26,877 shares in the company, valued at $10,349,795.16. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 248,418 shares of company stock valued at $95,927,097. 0.90% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Truist Financial boosted their price objective on Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 24th. Stifel Nicolaus upped their target price on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. Piper Sandler upped their target price on Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research report on Friday. Jefferies Financial Group upped their target price on Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research report on Friday. Finally, BTIG Research upped their target price on Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research report on Friday. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $396.17.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.